ライフサイエンスコーパス: erythropoiesis-stimulating agent

1 cluded death, infection rate, and dose of an erythropoiesis-stimulating agent.

2 increased morbidity and mortality related to erythropoiesis stimulating agents.

3 have lost response to or are ineligible for erythropoiesis-stimulating agents.

4 oxylases are currently in clinical trials as erythropoiesis-stimulating agents.

5 overanticoagulation, and adverse effects of erythropoiesis-stimulating agents.

6 OR downmodulation and trafficking, and novel erythropoiesis-stimulating agents.

7 o 4.7 g/dL) in the absence of transfusion or erythropoiesis-stimulating agents.

8 quiring surgery, and de novo prescription of erythropoiesis-stimulating agents.

9 ion and hyporesponsiveness to treatment with erythropoiesis-stimulating agents.

10 sions (42 [10%] vs seven [3%]; p=0.003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%];

11 Erythropoiesis stimulating agent administration in sTBI

12 Erythropoiesis-stimulating agent administration to patie

13 In view of the expense of erythropoiesis stimulating agents and the uncertainty of

14 Erythropoiesis-stimulating agents and blood transfusion

15 variability are because of the therapy with erythropoiesis-stimulating agents and/or iron or despite

16 should be reevaluated to include infection, erythropoiesis-stimulating agents, and blood transfusion

17 ecially in small children), reduced need for erythropoiesis-stimulating agents, and lower risk of blo

18 nty), and volume-targeted ventilation, early erythropoiesis-stimulating agents, and prophylactic etha

19 -and-see approach for asymptomatic patients, erythropoiesis-stimulating agents, androgens, or immunom

20 gradually moved away from the liberal use of erythropoiesis-stimulating agents as the main treatment

21 to hemorrhagic complications, in the use of erythropoiesis-stimulating agents at hospital discharge,

22 myelodysplasia requiring transfusion despite erythropoiesis-stimulating agents, based on the early re

23 ed reactively and resulted in lower doses of erythropoiesis-stimulating agent being administered.

24 ying AI, the combination of iron therapy and erythropoiesis-stimulating agents can improve anemia in

25 Addition of an erythropoiesis-stimulating agent could improve response

26 produstat, as compared with the conventional erythropoiesis-stimulating agent darbepoetin alfa, are u

27 vious studies suggest that administration of erythropoiesis-stimulating agents darbepoetin or erythro

28 Erythropoiesis-stimulating agents do not seem to benefit

29 Initial roxadustat dose depended on erythropoiesis-stimulating agent dose at screening for p

30 Erythropoiesis stimulating agent (ESA) administration ma

31 re conducted prior to current approaches for erythropoiesis stimulating agent (ESA) drug dosing guide

32 beling was applied for the first time to the erythropoiesis stimulating agent (ESA) products, which f

33 ), serum bicarbonate, and creatinine; use of erythropoiesis-stimulating agent (ESA) and iron; and imm

34 trials showed worse clinical outcomes in the erythropoiesis-stimulating agent (ESA) arm.

35 mmittee continues to recommend initiating an erythropoiesis-stimulating agent (ESA) as hemoglobin (Hb

36 rity trials, we compared vadadustat with the erythropoiesis-stimulating agent (ESA) darbepoetin alfa

37 Peginesatide is a peptide-based erythropoiesis-stimulating agent (ESA) that may have the

38 uated as an oral alternative to conventional erythropoiesis-stimulating agent (ESA) therapy.

39 In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lowe

40 Peginesatide, a synthetic peptide-based erythropoiesis-stimulating agent (ESA), is a potential t

41 pt than epoetin alfa for treating anaemia in erythropoiesis-stimulating agent (ESA)-naive patients wi

42 Poor response to erythropoiesis-stimulating agents (ESA) is associated wi

43 treating anemia of chronic kidney disease by erythropoiesis-stimulating agents (ESA) may improve surv

44 ed with non-iron-based phosphate binders and erythropoiesis-stimulating agents (ESA) to receive 24 we

45 Recombinant erythropoietin (EPO) analogs [erythropoiesis-stimulating agents (ESA)] are clinically

46 ations (oral iron, intravenous [IV] iron, or erythropoiesis stimulating agent [ESA]) at enrollment in

47 evel variability, especially with the use of erythropoiesis stimulating agents (ESAs) and iron.

48 Erythropoiesis stimulating agents (ESAs) have been repor

49 erythropoiesis and blunting the activity of erythropoiesis stimulating agents (ESAs).

50 nt practice by estimating its typical use of erythropoiesis-stimulating agents (ESAs) and intravenous

51 ic kidney disease; it is mainly treated with erythropoiesis-stimulating agents (ESAs) and iron.

52 The optimal use of erythropoiesis-stimulating agents (ESAs) and parenteral

53 Erythropoiesis-stimulating agents (ESAs) are commonly us

54 od cell transfusion dependence (RBC-TD), and erythropoiesis-stimulating agents (ESAs) are the mainsta

55 Erythropoiesis-stimulating agents (ESAs) are the standar

56 ho are on hemodialysis are hyporesponsive to erythropoiesis-stimulating agents (ESAs) because of anem

57 n supplementation alone and as an adjunct to erythropoiesis-stimulating agents (ESAs) compared with E

58 Non-placebo-controlled trials of erythropoiesis-stimulating agents (ESAs) comparing lower

59 African Americans require higher doses of erythropoiesis-stimulating agents (ESAs) during dialysis

60 The erythropoiesis-stimulating agents (ESAs) erythropoietin

61 safety of intravenous (IV) iron products and erythropoiesis-stimulating agents (ESAs) have resulted i

62 Small studies showed that erythropoiesis-stimulating agents (ESAs) improve subject

63 m (PPS) and changes to dosing guidelines for erythropoiesis-stimulating agents (ESAs) in 2011 appear

64 ed controlled trials assessing the effect of erythropoiesis-stimulating agents (ESAs) in critically i

65 xylase inhibitors (PHIs) are as effective as erythropoiesis-stimulating agents (ESAs) in increasing h

66 ional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete

67 Clinical Oncology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients wit

68 e to high doses or a high cumulative dose of erythropoiesis-stimulating agents (ESAs) may contribute

69 l-based approaches to anemia management with erythropoiesis-stimulating agents (ESAs) may result in u

70 investigated genetic markers associated with erythropoiesis-stimulating agents (ESAs) response in LR-

71 The use of erythropoiesis-stimulating agents (ESAs) such as erythro

72 Erythropoiesis-stimulating agents (ESAs) were prescribed

73 ony-stimulating factor support was required; erythropoiesis-stimulating agents (ESAs) were used at th

74 ith renal anemia are frequently treated with erythropoiesis-stimulating agents (ESAs), which are dyna

75 odysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a respons

76 are not responding to or are ineligible for erythropoiesis-stimulating agents (ESAs).

77 stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs).

78 analysis to determine the patterns of use of erythropoiesis-stimulating agents (ESAs).

79 ir management with RBV dose reduction and/or erythropoiesis-stimulating agents (ESAs).

80 ism and concern of potential harm from using erythropoiesis-stimulating agents (ESAs).

81 d range from supportive care with or without erythropoiesis-stimulating agents for patients with low-

82 Among patients who were not receiving erythropoiesis-stimulating agents, hemoglobin increased

83 Among patients who were receiving erythropoiesis-stimulating agents, hemoglobin increased

84 implementation of restrictions on the use of erythropoiesis-stimulating agents in cancer may impact b

85 Immunosuppressants, erythropoiesis-stimulating agents in combination with gr

86 NDATION 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild

87 on supplements to potentiate the response to erythropoiesis-stimulating agents in patients with renal

88 s indicating a possible beneficial effect of erythropoiesis-stimulating agents in the treatment of an

89 thus, this study does not support the use of erythropoiesis-stimulating agents in this subset of pati

90 discuss issues more specifically related to erythropoiesis-stimulating agents, including epoetins, a

91 survival pathways, the development of novel erythropoiesis-stimulating agents, increasing evidence f

92 This long-acting erythropoiesis-stimulating agent is as safe as conventio

93 in less than 100 g/L (10 g/dL) and/or use of erythropoiesis-stimulating agents, leukocyte count more

94 Both pharmacologic features and dosing of erythropoiesis-stimulating agents may lead to cyclic pat

95 cules compared with placebo (superiority) or erythropoiesis-stimulating agents (noninferiority).

96 ansfusions for reasons such as resistance to erythropoiesis-stimulating agents or cardiovascular inst

97 of major cardiovascular events compared with erythropoiesis-stimulating agents or placebo.

98 was refractory to or unlikely to respond to erythropoiesis-stimulating agents or who had discontinue

99 nofsky performance status (KPS), exposure to erythropoiesis-stimulating agents, presence of central v

100 Erythropoiesis stimulating agents remain the first-line

101 Trials raising concerns about erythropoiesis-stimulating agents, revisions to their la

102 Additionally, early erythropoiesis-stimulating agents (RR, 0.68 [95% CI, 0.5

103 mia is a common symptom in MDS, and although erythropoiesis-stimulating agents such as erythropoietin

104 For patients with lower-risk MDS, erythropoiesis stimulating agents, such as recombinant h

105 sed resistance to supraphysiologic levels of erythropoiesis-stimulating agent, supporting the hypothe

106 to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offe

107 lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effectiv

108 Despite the near universal use of erythropoiesis-stimulating agents, there are still occas

109 d from myelodysplastic syndromes, relying on erythropoiesis-stimulating agents to cope with anemia, a

110 And for emerging erythropoiesis-stimulating agents, to what extent do act

111 ems have provided strong stimuli to decrease erythropoiesis-stimulating agent use and increase intrav

112 and ferritin 50 ng/ml or more without recent erythropoiesis-stimulating agent use were randomized (1:

113 The median monthly dose of an erythropoiesis-stimulating agent was 29,757 IU in the hi

114 Treatment with lenalidomide and erythropoiesis-stimulating agents was shown to be an ind

115 e reversed, treatment options are limited to erythropoiesis-stimulating agents with or without intrav

116 Treatment studies have focused on the use of erythropoiesis-stimulating agents, with recent trials sh